Latest Breaking News On - Drug creation - Page 1 : comparemela.com

Absci to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

VANCOUVER, Wash. and NEW YORK, May 28, 2024 Absci Corporation , a data-first generative AI drug creation company, today announced the company will be participating in the upcoming Goldman Sachs.

New yorkUnited statesBritish columbiaAlex khanGoldman sachsInnovation centerAbsci corporation nasdaqAi research labAnnual global healthcare conferenceDrug creationNew york citySecurities act

Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI

IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly afterVANCOUVER, Wash. and NEW YORK, Feb. 21, 2024 Absci Corporation , a data-first generative AI drug creation.

British columbiaNew yorkUnited statesSean mcclainAlex khanInnovation centerSecurities exchangeExchange commissionAbsci corporation nasdaqAi research labDrug creationNew york citySecurities actSecurities exchange act

Absci to Participate in the 42nd Annual J P Morgan Healthcare Conference

VANCOUVER, Wash. and NEW YORK, Dec. 28, 2023 Absci Corporation , a generative AI drug creation company, today announced the company will be participating in the upcoming 42nd Annual J.P. Morgan.

San franciscoUnited statesBritish columbiaNew yorkAlex khanAbsci corporation nasdaqAi research labInnovation centerHealthcare conferenceDrug creationNew york citySecurities act

Absci Corporation (ABSI) Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate

Absci Corporation (ABSI) Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Sean mcclainAbsci corporation nasdaqAbsci corporationIntegrated drug creationAbsci founderDrug creationSenior vice presidentBiologics engineeringOncology targeted delivery

Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate

Collaboration Combines Absci’s AI Antibody Drug Creation Platform with AstraZeneca’s Expertise in Oncology Research and DevelopmentVANCOUVER, Wash., Dec. 04, 2023 Absci Corporation , a.

New yorkUnited statesBritish columbiaSean mcclainAlex khanAstrazeneca expertise in oncology researchAi research labAbsci corporation nasdaqInnovation centerExchange commissionSecurities exchangeCollaboration combines absciDrug creation platformOncology researchIntegrated drug creationAbsci founder